Adult-onset vitelliform detachment unresponsive to monthly intravitreal ranibizumab.
A 72-year-old woman with decreased visual acuity secondary to an adult-onset vitelliform detachment was treated with three monthly intravitreal injections of 0.5 mg of ranibizumab. Treatment response was monitored by visual acuity and by the eye-tracking feature of the Heidelberg Spectralis spectral domain optical coherence tomography (Heidelberg Engineering, Inc., Carlsbad, CA). There was no improvement in functional or anatomic outcome after three monthly injections of ranibizumab. The eye-tracking feature of the spectral domain optical coherence tomography system was highly accurate in making comparisons between serial optical coherence tomography examinations.
LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and Throat Hospital, New York, NY, USA.
Sushma
S
Kandula
Sandrine
S
Zweifel
K Bailey
KB
Freund
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D000069579:Ranibizumab; D012163:Retinal Detachment / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014786:Vision Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D014792:Visual Acuity / Q000502:physiology; D057826:Vitelliform Macular Dystrophy / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab